journal
https://read.qxmd.com/read/38519390/immunotherapy-rechallenge-after-checkpoint-inhibitor-induced-hemophagocytic-lymphohistiocytosis-a-case-report-and-literature-review
#1
Dorien Geusens, Daan Dierickx, Saskia Carton, Eric Van Cutsem, Jeroen Dekervel
No abstract text is available yet for this article.
February 21, 2024: Clinical Colorectal Cancer
https://read.qxmd.com/read/38519391/ongoing-clinical-trials-and-future-research-scenarios-of-circulating-tumor-dna-for-the-treatment-of-metastatic-colorectal-cancer
#2
REVIEW
Laura Roazzi, Giorgio Patelli, Katia Bruna Bencardino, Alessio Amatu, Erica Bonazzina, Federica Tosi, Brunella Amoruso, Anna Bombelli, Sara Mariano, Stefano Stabile, Camillo Porta, Salvatore Siena, Andrea Sartore-Bianchi
Liquid biopsy using circulating tumor DNA (ctDNA) has emerged as a minimally invasive, timely approach to provide molecular diagnosis and monitor tumor evolution in patients with cancer. Since the molecular landscape of metastatic colorectal cancer (mCRC) is substantially heterogeneous and dynamic over space and time, ctDNA holds significant advantages as a biomarker for this disease. Numerous studies have demonstrated that ctDNA broadly recapitulates the molecular profile of the primary tumor and metastases, and have mainly focused on the genotyping of RAS and BRAF, that is propaedeutic for anti-EGFR treatment selection...
February 16, 2024: Clinical Colorectal Cancer
https://read.qxmd.com/read/38365567/consideration-of-metastasis-directed-therapy-for-patients-with-metastatic-colorectal-cancer-expert-survey-and-systematic-review
#3
JOURNAL ARTICLE
Eric D Miller, Brett G Klamer, Jordan M Cloyd, Timothy M Pawlik, Terence M Williams, Kathryn E Hitchcock, Paul B Romesser, Harvey J Mamon, Kimmie Ng, Sepideh Gholami, George J Chang, Christopher J Anker
BACKGROUND: A survey of medical oncologists (MOs), radiation oncologists (ROs), and surgical oncologists (SOs) who are experts in the management of patients with metastatic colorectal cancer (mCRC) was conducted to identify factors used to consider metastasis-directed therapy (MDT). MATERIALS AND METHODS: An online survey to assess clinical factors when weighing MDT in patients with mCRC was developed based on systematic review of the literature and integrated with clinical vignettes...
January 30, 2024: Clinical Colorectal Cancer
https://read.qxmd.com/read/38336555/neoadjuvant-immunotherapy-with-ipilimumab-plus-nivolumab-in-mismatch-repair-deficient-microsatellite-instability-high-colorectal-cancer-a-preliminary-report-of-case-series
#4
JOURNAL ARTICLE
Tao Pan, Hui Yang, Wu-Yi Wang, Yuan-Yi Rui, Zi-Jian Deng, Yung-Chang Chen, Chao Liu, Hai Hu
BACKGROUND: Although ipilimumab plus nivolumab have significantly improved the survival of metastatic colorectal cancer (CRC) with mismatch repair deficient (dMMR) /microsatellite instability-high (MSI-H), the data on neoadjuvant setting is limited. PATIENTS AND METHODS: We enrolled 11 patients with advanced dMMR/MSI-H CRC. 10 patients were locally advanced and 1 was metastatic. Ten patients were treated with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg), and 1 patient was treated with 1 dose of ipilimumab (1 mg/kg) and 2 doses of nivolumab (3 mg/kg) with 2 cycles...
January 18, 2024: Clinical Colorectal Cancer
https://read.qxmd.com/read/38331650/plasma-angiogenic-factors-as-predictors-of-the-efficacy-of-second-line-chemotherapy-combined-with-angiogenesis-inhibitors-in-metastatic-colorectal-cancer-results-from-the-gi-screen-crc-ukit-study
#5
JOURNAL ARTICLE
Satoshi Yuki, Kentaro Yamazaki, Yu Sunakawa, Hiroya Taniguchi, Hideaki Bando, Manabu Shiozawa, Tomohiro Nishina, Hisateru Yasui, Akiyoshi Kanazawa, Koji Ando, Yosuke Horita, Masahiro Goto, Naohiro Okano, Toshikazu Moriwaki, Taroh Satoh, Akihito Tsuji, Kaname Yamashita, Chiharu Asano, Yukiko Abe, Shogo Nomura, Takayuki Yoshino
BACKGROUND: The significance of angiogenic factors as predictors of second-line (2L) chemotherapy efficacy when combined with angiogenesis inhibitors for metastatic colorectal cancer (mCRC) remains unestablished. PATIENTS AND METHODS: In this multicenter prospective observational study, 17 angiogenic factors were analyzed in plasma samples collected at pretreatment and progression stages using a Luminex multiplex assay. Patients who received chemotherapy plus bevacizumab (BEV group), FOLFIRI plus ramucirumab (RAM group), or FOLFIRI plus aflibercept (AFL group) as the 2L treatment were included...
January 18, 2024: Clinical Colorectal Cancer
https://read.qxmd.com/read/38242766/adjuvant-chemotherapy-for-older-patients-with-stage-iii-colorectal-cancer-a-real-world-analysis-of-treatment-recommendations-treatment-administered-and-impact-on-cancer-recurrence
#6
JOURNAL ARTICLE
Oliver Piercey, Hui-Li Wong, Clara Leung, Yat Hang To, Valerie Heong, Margaret Lee, Jeanne Tie, Malcolm Steel, Justin M Yeung, Jacob McCormick, Peter Gibbs, Rachel Wong
BACKGROUND: A substantial proportion of patients with stage III colorectal cancer (CRC) are older than 70 years. Optimal adjuvant chemotherapy (AC) for older patients (OP) continues to be debated, with subgroup analyses of randomized trials not demonstrating a survival benefit from the addition of oxaliplatin to a fluoropyrimidine backbone. PATIENTS AND METHODS: We analyzed the multisite Australian ACCORD registry, which prospectively collects patient, tumor and treatment data along with long term clinical follow-up...
January 11, 2024: Clinical Colorectal Cancer
https://read.qxmd.com/read/38172003/clinical-management-of-gastrointestinal-and-liver-toxicities-of-immune-checkpoint-inhibitors
#7
REVIEW
Kevin Mok, Claudia Wu, Stephen Chan, Grace Wong, Vincent Wai-Sun Wong, Brigette Ma, Rashid Lui
Immune checkpoint inhibitors have transformed the treatment paradigm for various types of cancer. Nonetheless, with the utilization of these groundbreaking treatments, immune-related adverse events (irAEs) are increasingly encountered. Colonic and hepatic involvement are among the most frequently encountered irAEs. Drug-induced side effects, infectious causes, and tumor-related symptoms are the key differentials for irAE complications. Potential risk factors for the development of irAEs include combination use of immune checkpoint inhibitors, past development of irAEs with other immunotherapy treatments, certain concomitant drugs, and a pre-existing personal or family history of autoimmune illness such as inflammatory bowel disease...
December 16, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/38216367/salvage-treatment-of-recurrent-or-persistent-anal-squamous-cell-carcinoma-the-role-of-multi-modality-therapy
#8
JOURNAL ARTICLE
Ethan P Damron, Jordan McDonald, Michael K Rooney, Prajnan Das, Ethan B Ludmir, Bruce D Minsky, Craig Messick, George J Chang, Van K Morris, Emma B Holliday
BACKGROUND: The standard treatment for recurrent or persistent anal squamous cell carcinoma is surgical salvage, but disease control and survival are suboptimal. PATIENTS/METHODS: Patients treated for recurrent or persistent anal squamous cell carcinoma at our institution from 2002 to 2022 were included. Patients were classified by type of salvage treatment received: surgery alone vs. reirradiation followed by surgery and by whether they received intraoperative radiation at the time of surgery...
December 13, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/38151358/prognostic-impact-of-primary-tumor-sidedness-in-stage-iii-colorectal-cancer-real-world-evidence-from-a-brazilian-cohort
#9
JOURNAL ARTICLE
Bruno Medonça Protásio, Tiago Biachi de Castria, Renato Natalino, Flávia R Mangone, Daniel Fernandes Saragiotto, Jorge Sabbaga, Paulo M Hoff, Roger Chammas
BACKGROUND: Primary tumor sidedness (PTS) is an independent prognostic factor in patients with metastatic colorectal cancer (CRC), with a worse prognosis for right-sided tumors. There are limited data on the prognostic impact of PTS in stage III CRC. The main objective of this study was to analyze the prognostic impact of PTS in stage III CRC. PATIENTS AND METHODS: A retrospective and uni-institutional cohort study was performed in an oncology reference center. Patients with stage III CRC treated with a 5-fluorouracil and oxaliplatin-based chemotherapy regimen (mFLOX regimen) from October 2007 to February 2013 were included...
December 10, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/37949790/management-of-older-adults-with-colorectal-cancer-the-role-of-geriatric-assessment
#10
REVIEW
Ahmet Anil Ozluk, Darryl Outlaw, Mehmet Akce, Mackenzie E Fowler, Daniel L Hess, Smith Giri, Grant R Williams
Older adults share a growing burden of cancer morbidity and mortality. This is present across the spectrum of oncologic diagnoses and is particularly true with colorectal cancer (CRC), where older adults continue to share the burden of diagnoses. However, optimal cancer treatment decision making in older adults remains a significant challenge, as the majority of previous clinical trials shaping the current treatment landscape have focused on younger patients, often with more robust performance status and fewer medical comorbid conditions...
December 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/37925305/life-after-colorectal-cancer-survivorship-the-road-less-traveled
#11
EDITORIAL
Mehmet Sitki Copur
No abstract text is available yet for this article.
December 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/37704538/plasma-cetuximab-concentrations-correlate-with-survival-in-patients-with-advanced-kras-wild-type-colorectal-cancer
#12
RANDOMIZED CONTROLLED TRIAL
Di Maria Jiang, Shruti Parshad, Luna Zhan, Hao-Wen Sim, Lillian L Siu, Geoffrey Liu, Jeremy D Shapiro, Timothy J Price, Derek J Jonker, Christos S Karapetis, Andrew H Strickland, Wenjiang Zhang, Mark Jeffery, Dongsheng Tu, Siobhan Ng, Sabe Sabesan, Jenny Shannon, Amanda Townsend, Chris J O'Callaghan, Eric X Chen
BACKGROUND: Cetuximab is a standard of care therapy for patients with RAS wild-type (WT) advanced colorectal cancer. Limited data suggest a wide variation in cetuximab plasma concentrations after standard dosing regimens. We correlated cetuximab plasma concentrations with survival and toxicity. METHODS: The CO. 20 study randomized patients with RAS WT advanced colorectal cancer in a 1:1 ratio to cetuximab 400 mg/m2 intravenously followed by weekly maintenance of 250 mg/m2 , plus brivanib 800 mg orally daily or placebo...
December 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/38103947/a-phase-1-study-of-cabozantinib-and-trifluridine-tipiracil-in-metastatic-colorectal-adenocarcinoma
#13
JOURNAL ARTICLE
Farshid Dayyani, Jasmine Balangue, Jennifer Valerin, Matthew J Keating, Jason A Zell, Thomas H Taylor, May T Cho
INTRODUCTION: This study determined the safety and recommended phase 2 dose (RP2D) of the multikinase inhibitor cabozantinib in combination with trifluridine/tipiracil (FTD/TPI) in refractory metastatic colorectal carcinoma (mCRC). PATIENTS AND METHODS: Single institution investigator-initiated phase 1 study using 3+3 design. Eligible mCRC patients had received prior standard regimens. Cabozantinib was given orally (p.o.) at 20 mg (dose level [DL] 0) or 40 mg (DL 1) daily on days 1-28, and FTD/TPI p...
November 27, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/38177002/efficacy-of-pyrotinib-with-without-trastuzumab-in-treatment-refractory-her2-positive-metastatic-colorectal-cancer-result-from-a-prospective-observational-study
#14
JOURNAL ARTICLE
Haojie Zhou, Minzhi Lv, Wei Li, Yan Wang, Jing Wu, Qing Liu, Tianshu Liu, Yuehong Cui, Qian Li
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) is a promising therapeutic target in metastatic colorectal cancer (mCRC). This study was to evaluate the efficacy and safety of pyrotinib alone or pyrotinib with trastuzumab in patients with HER2-positive mCRC. PATIENTS AND METHODS: In this prospective observational study, patients with HER2 positive, Ras Sarcoma Viral Oncogene Homolog (RAS) wild type mCRC who received at least one standard treatment of palliative chemotherapy were enrolled...
November 19, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/38007297/real-world-safety-and-effectiveness-of-a-bevacizumab-biosimilar-abp-215-in-metastatic-colorectal-cancer-patients-in-canada
#15
JOURNAL ARTICLE
Winson Y Cheung, Setareh Samimi, Kim Ma, Gregory John Knight, Shaqil Kassam, Bruce Colwell, Annie Beaudoin, Mark David Vincent, Mateya Trinkaus, Alain Filion, Katerine Marquis, Hatim Karachiwala, Timothy Asmis, Lucas Sideris, Rajvi J Wani, Elaine Ngan, Naila Inam, Yinhao Du, Leyla Nunez, Maria Eberg, Mistre Alemayehu, Pierre-Francois Meyer, Johanna Mancini, Carlye Cirone Morris
BACKGROUND: ABP 215 is a biosimilar to the reference product, bevacizumab, and was one of the first biosimilars approved by Health Canada for the first-line treatment of metastatic colorectal cancer (mCRC). This study aimed to address gaps in real-world evidence (RWE) including patient characteristics, treatment safety (primary objective), and effectiveness (secondary objective) for first-line ABP 215 therapy in Canadian patients with mCRC. MATERIALS AND METHODS: Retrospective data were collected in 2 waves, at least 1 year (Wave 1) or 2 years (Wave 2) after commercial availability of ABP 215 at each participating site...
October 28, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/37980215/propensity-score-matched-analysis-of-survival-outcomes-of-adjuvant-therapy-in-stage-ii-iii-signet-ring-cell-carcinoma-of-the-colon
#16
JOURNAL ARTICLE
Sameh Hany Emile, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Victor Strassmann, Steven D Wexner
BACKGROUND: Colonic signet ring cell carcinoma (SRCC) is a mucinous adenocarcinoma subtype often associated with poor prognosis. This study assessed the survival benefits of adjuvant therapy after curative resection of stage II-III colonic SRCC. METHODS: This was a retrospective analysis of outcomes of adjuvant therapy in colonic SRCC using National Cancer Database (2010-2019) data. Patients who received adjuvant therapy were matched to those who did not use the nearest neighbor propensity-score matching...
October 26, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/37932152/cost-effectiveness-of-the-new-combination-trifluridine-tipiracil-plus-bevacizumab-for-the-third-line-treatment-for-metastatic-colorectal-cancer-in-italy
#17
JOURNAL ARTICLE
Jacopo Giuliani, Beatrice Mantoan, Daniela Mangiola, Marco Muraro, Giuseppe Napoli, Marina Tommasi, Francesco Fiorica, Marta Mandarà
No abstract text is available yet for this article.
October 14, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/37980216/optimizing-fecal-occult-blood-test-fobt-colorectal-cancer-screening-using-gut-bacteriome-as-a-biomarker
#18
JOURNAL ARTICLE
Moumita Roy Chowdhury, Karina Gisèle Mac Si Hone, Karine Prévost, Philippe Balthazar, Mariano Avino, Mélina Arguin, Jude Beaudoin, Mandy Malick, Michael Desgagné, Gabriel Robert, Michelle Scott, Jean Dubé, Isabelle Laforest-Lapointe, Eric Massé
BACKGROUND: Colorectal cancer (CRC) is a major cause of cancer mortality in the world. One of the most widely used screening tests for CRC is the immunochemical fecal occult blood test (iFOBT), which detects human hemoglobin from patient's stool sample. Although it is highly efficient in detecting blood from patients with gastro-intestinal lesions, such as polyps and cancers, the iFOBT has a high rate of false positive discovery. Recent studies suggested gut bacteria as a promising noninvasive biomarker for improving the diagnosis of CRC...
October 13, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/37919185/effectiveness-of-biologic-agents-among-hispanic-patients-with-metastatic-colorectal-cancer
#19
JOURNAL ARTICLE
Riya Patel, Abdissa Negassa, Seda S Tolu, Ana Acuna-Villaorduna, Sanjay Goel
BACKGROUND: Randomized clinical trials have defined the survival advantage with the addition of biologic drugs to chemotherapy in patients with metastatic colorectal cancer (mCRC). Under representation of Hispanics contributes to poorly defined outcomes in this group. We aim to determine whether the real-world benefit of biologics extends to Hispanics using a comparative effectiveness research approach. METHODS: This retrospective cohort study included all treatment centers contributing to SEER registry with available claims in the SEER-Medicare linked database (2001-2011) and 2 hospitals (2004-2016) catering to minorities...
October 6, 2023: Clinical Colorectal Cancer
https://read.qxmd.com/read/37838522/secondary-primary-cancer-risk-after-radiation-therapy-in-rectal-cancer-a-population-based-cohort-study-with-propensity-score-matching
#20
JOURNAL ARTICLE
Anne Schlesinger-Raab, Gabriele Schubert-Fritschle, Mia Kim, Jens Werner, Claus Belka, Hendrik Wolff, Ayman Agha, Martin Fuchs, Helmut Friess, Stefanie Combs, Barbara Häussler, Jutta Engel, Kathrin Halfter
BACKGROUND: It remains unclear whether radiation therapy (RT) has an impact on the development of secondary primary cancer (SC) in rectal cancer (RC) patients, especially within the true pelvis. AIM: To examine the incidence of SC in a population-based cohort of RC after surgical treatment with or without radiation therapy (RT, NRT). PATIENTS AND METHODS: The epidemiological cohort consisting of 13,919 RC patients with primary M0 stage diagnosed between 1998 and 2019 was collected from cancer registry data of Upper Bavaria...
September 19, 2023: Clinical Colorectal Cancer
journal
journal
39741
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.